We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?
Read MoreHide Full Article
Key Takeaways
CLOV is likely to post Q2 EPS of 3 cents and sales of $482.5M, up 200% and 35.4%, respectively, y/y.
CLOV's Clover Assistant cut CHF hospitalizations by 18%, showing early cost and care management benefits.
CLOV's Counterpart Health expands tech reach, but Q2 financial impact from non-insurance revenue is limited.
Clover Health Investments (CLOV - Free Report) is slated to release second-quarter 2025 results on Aug. 5, after market close. The Zacks Consensus Estimate for earnings and revenues is pegged at 3 cents per share and $482.5 million, respectively.
The earnings estimate, which has remained stable over the past 30 days, indicates a whopping 200% growth year over year. The Zacks Consensus Estimate for quarterly revenues suggests a year-over-year increase of 35.4%.
Image Source: Zacks Investment Research
The consensus mark for 2025 revenues is pegged at $1.89 billion, implying a rise of 37.7% year over year, and the same for EPS is pinned at 11 cents, suggesting a year-over-year decline of 21.4%. This Medicare Advantage insurer’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 114.58%.
Q2 Earnings Whispers for Clover
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: CLOV has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Clover Health heads into its second-quarter earnings release next week riding on its stellar first-quarter results with 30% Medicare Advantage (MA) membership growth and a 279% year-over-year surge in adjusted EBITDA. The upcoming results are expected to reflect continued benefits from its tech-enabled care delivery model and strategic member onboarding efforts.
A key tailwind that is likely to have sustained performance is the expansion and deeper integration of Clover Assistant (CA), its AI-powered clinical decision support tool. CA’s role in early disease detection and chronic care management has already shown quantifiable outcomes.
A May whitepaper from its subsidiary, Counterpart Health, highlighted an 18% reduction in hospitalizations and 25% lower 30-day readmissions in congestive heart failure (CHF) patients managed by CA-equipped PCPs. These results are not only clinically meaningful but may also translate into cost efficiencies — potentially easing pressure on the company’s Insurance Benefit Expense Ratio (“BER”), which was 86.1% in the first quarter.
Member growth, particularly in core markets like New Jersey, remains robust on the back of strong plan retention and disciplined benefit design. New members onboarded during the AEP and OEP seasons were reportedly utilizing care at expected levels, reinforcing the strength of cohort management strategies. This is likely to have resulted in increased sales during the soon-to-be-reported quarter.
On the technology commercialization front, CLOV’s Counterpart Health continues to scale, bringing the Assistant’s capabilities to non-Clover plans via SaaS-style arrangements. Management remains optimistic about its long-term potential. However, this is unlikely to have had a material impact in the second quarter.
Investors are likely to ask questions on updates about utilization trends, HCC risk adjustment transitions and the sustainability of SG&A leverage during the second-quarter earnings call.
CLOV Price Performance & Valuation
On a year-to-date basis, shares of CLOV have declined 8.2%, underperforming its close peers, Alignment Healthcare (ALHC - Free Report) and Oscar Health (OSCR - Free Report) and the Medical Info Systems sector.
Image Source: Zacks Investment Research
In terms of valuation, Clover Health trades at a forward 12-month P/S of 0.65 — above Alignment Healthcare (0.62) and Oscar Health (0.31). Despite Alignment Healthcare and Oscar Health offering lower multiples, CLOV’s premium reflects stronger growth expectations.
CLOV vs ALHC
Image Source: Zacks Investment Research
CLOV vs OSCR
Image Source: Zacks Investment Research
Buy Clover Stock Ahead of Q2 Results?
Clover Health continues to demonstrate solid execution with strong MA membership growth, improved clinical outcomes via Clover Assistant and expanding Counterpart Health traction. Its near-term upside appears fairly priced in. The company’s profitability remains modest, with Insurance BER still elevated and full-year gains partly dependent on favorable seasonality and continued cost control.
Additionally, while Counterpart holds promise, material revenue contribution is still evolving. Given these factors and pending confirmation of sustainable margin improvement in the second half of 2025, investors should continue to hold the stock. However, new investors may await clearer visibility into operating leverage and execution on non-insurance revenues before adding the stock to their portfolio.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?
Key Takeaways
Clover Health Investments (CLOV - Free Report) is slated to release second-quarter 2025 results on Aug. 5, after market close. The Zacks Consensus Estimate for earnings and revenues is pegged at 3 cents per share and $482.5 million, respectively.
The earnings estimate, which has remained stable over the past 30 days, indicates a whopping 200% growth year over year. The Zacks Consensus Estimate for quarterly revenues suggests a year-over-year increase of 35.4%.
Image Source: Zacks Investment Research
The consensus mark for 2025 revenues is pegged at $1.89 billion, implying a rise of 37.7% year over year, and the same for EPS is pinned at 11 cents, suggesting a year-over-year decline of 21.4%. This Medicare Advantage insurer’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 114.58%.
Q2 Earnings Whispers for Clover
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: CLOV has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Factors to Note Ahead of CLOV’s Q2 Results
Clover Health heads into its second-quarter earnings release next week riding on its stellar first-quarter results with 30% Medicare Advantage (MA) membership growth and a 279% year-over-year surge in adjusted EBITDA. The upcoming results are expected to reflect continued benefits from its tech-enabled care delivery model and strategic member onboarding efforts.
A key tailwind that is likely to have sustained performance is the expansion and deeper integration of Clover Assistant (CA), its AI-powered clinical decision support tool. CA’s role in early disease detection and chronic care management has already shown quantifiable outcomes.
A May whitepaper from its subsidiary, Counterpart Health, highlighted an 18% reduction in hospitalizations and 25% lower 30-day readmissions in congestive heart failure (CHF) patients managed by CA-equipped PCPs. These results are not only clinically meaningful but may also translate into cost efficiencies — potentially easing pressure on the company’s Insurance Benefit Expense Ratio (“BER”), which was 86.1% in the first quarter.
Member growth, particularly in core markets like New Jersey, remains robust on the back of strong plan retention and disciplined benefit design. New members onboarded during the AEP and OEP seasons were reportedly utilizing care at expected levels, reinforcing the strength of cohort management strategies. This is likely to have resulted in increased sales during the soon-to-be-reported quarter.
On the technology commercialization front, CLOV’s Counterpart Health continues to scale, bringing the Assistant’s capabilities to non-Clover plans via SaaS-style arrangements. Management remains optimistic about its long-term potential. However, this is unlikely to have had a material impact in the second quarter.
Investors are likely to ask questions on updates about utilization trends, HCC risk adjustment transitions and the sustainability of SG&A leverage during the second-quarter earnings call.
CLOV Price Performance & Valuation
On a year-to-date basis, shares of CLOV have declined 8.2%, underperforming its close peers, Alignment Healthcare (ALHC - Free Report) and Oscar Health (OSCR - Free Report) and the Medical Info Systems sector.
Image Source: Zacks Investment Research
In terms of valuation, Clover Health trades at a forward 12-month P/S of 0.65 — above Alignment Healthcare (0.62) and Oscar Health (0.31). Despite Alignment Healthcare and Oscar Health offering lower multiples, CLOV’s premium reflects stronger growth expectations.
CLOV vs ALHC
Image Source: Zacks Investment Research
CLOV vs OSCR
Image Source: Zacks Investment Research
Buy Clover Stock Ahead of Q2 Results?
Clover Health continues to demonstrate solid execution with strong MA membership growth, improved clinical outcomes via Clover Assistant and expanding Counterpart Health traction. Its near-term upside appears fairly priced in. The company’s profitability remains modest, with Insurance BER still elevated and full-year gains partly dependent on favorable seasonality and continued cost control.
Additionally, while Counterpart holds promise, material revenue contribution is still evolving. Given these factors and pending confirmation of sustainable margin improvement in the second half of 2025, investors should continue to hold the stock. However, new investors may await clearer visibility into operating leverage and execution on non-insurance revenues before adding the stock to their portfolio.